Guideline-conformity of outpatient COPD management by pneumologists;COPD-management nach aktuellen leitlinien bei niedergelassenen pneumologen

Pneumologie

Volumn 60, Issue 7, 2006, Pages 395-400

  Glaab, T ^a   Banik, N ^b   Trautmann, M ^a   Hellmann, A ^c   Wencker, Marion ^a,d  

^a Medizinischer Fachbereich Pneumologie   (Germany)

^b GLAXOSMITHKLINE   (Germany)

^c Bundesverband der Pneumologen   (Germany)

^d Glaxo Smith Kline   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE CLASSIFICATION; EVIDENCE BASED MEDICINE; GERMANY; HUMAN; OUTPATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PULMONARY REHABILITATION; QUALITY OF LIFE; QUESTIONNAIRE; SPIROMETRY;

CROSS-SECTIONAL STUDIES; GERMANY; HUMANS; PRACTICE GUIDELINES; PULMONARY DISEASE (SPECIALTY); PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRES; SPIROMETRY;

EID: 33745977102     PISSN: 09348387     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-932166     Document Type: Article

References (15)

1. Fabel H, Konietzko N (Hrsg). Weißbuch Lunge 2005. Stuttgart: Thieme, 2005: 29-32
2. Weite T, Behnke M, Piecyk A et al. Prevalence of respiratory symptoms and lung function impairment in patients treated by German general practitioners. Eur Respir J 2000; 16 (Suppl 31): S111
3. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Bethesda: National Heart, Lung and Blood Institute. GOLD website (www.goldcopd.com), Update 2004
4. Worth H, Buhl R, Cegla U et al. Leitlinie der Deutschen Atemwegsliga und der Deutschen Gesellschaft für Pneumologie zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem. Pneumologie 2002; 56: 703-737
5. Pauwels RA, Buist AS, Ma P et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): Executive summary. Respir Care 2001; 46: 798-825
6. Woolf S, Grol R, Hutchinson A et al. Potential benefits, limitations, and harms of clinical guidelines. BMJ 1999; 318: 527-530
7. Harrold L, Field T, Gurwitz J. Knowledge, patterns of care, and outcomes of care for generalists and specialists. J Gen Intern Med 1999; 14: 499-511
8. National Institute for Clinical Excellence (NICE). Chronic obstructive pulmonary disease: national clinical guideline for management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004; 59 (Suppl 1): 1-232
9. Vestbo J, Lange P. Can GOLD stage 0 provide information of prognostic value in chronic obstructive pulmonary disease? Am J Respir Crit Care Med 2002; 166: 329-332
10. Troosters T, Casaburi R, Gosselink R et al. Pulmonary rehabilitation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172: 19-38
11. Schols A, Wesseling G, Kester A et al. Dose dependent increased mortality risk in COPD patients treated with oral glucocorticoids. Eur Respir J 2001; 17: 337-342
12. Decramer M, Celli B, Tashkin D et al. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the Uplift trial. J COPD 2004; 1: 303-312
13. The TORCH Study Group. The TORCH (Towards a revolution in COPD health) survival study protocol. Eur Respir J 2004; 24: 206-210
14. Ramsey S. Suboptimal medical therapy in COPD. Exploring the causes and consequences. Chest 2000; 117: 33-37
15. Rutschmann O, Janssens J, Vermeulen Bet al. Knowledge of guidelines for the management of COPD: A survey of primary care physicians. Respir Med 2004; 98: 932-937